** Hong Kong-listed shares of RemeGen Co Ltd 9995.HK jump 7% to HK$52.90, their highest levels since April 2023

** Shanghai-listed stock of the Chinese biopharmaceuticals developer 688331.SS rise 4.7% to 59.33 yuan, its highest point since April 2024

** Nomura maintains "neutral" rating but lifts TP of RemeGen Hong Kong shares to HK$47.6 from HK$16.37 and the Shanghai stock to 57.76 yuan from 29.80 yuan, citing the firm's new H-shares issuance improves its financials

** "We believe the current strong sentiment on biotech names provides a good timing window for the company to make this issuance," Nomura said, adding the proceeds will strengthen the company's constrained cash position

** RemeGen says to issue 19 mln H-shares at HK$42.44 apiece, raising HK$806.4 mln ($103 mln)

** Hang Seng Biotech Index .HSHKBIO rises 2.2% and Hang Seng Index .HSI gains 0.7%

** YTD, Hong Kong stock up 258.3%, Shanghai shares up 90.5%

($1 = 7.8298 Hong Kong dollars)

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))